“There is a great need for safe and effective therapies for treatment of infantile spasms (IS) and Lennox-Gastaut syndrome (LGS). Based on anecdotal reports and limited experience in an open-label trial, cannabidiol (CBD) has received tremendous attention as a potential treatment for pediatric epilepsy, especially Dravet syndrome.
We sought to document the experiences of children with IS and/or LGS who have been treated with CBD-enriched cannabis preparations.
Perceived efficacy and tolerability were similar across etiologic subgroups.
Eighty-five percent of all parents reported a reduction in seizure frequency, and 14% reported complete seizure freedom.
Reported side effects were far less common during CBD exposure, with the exception of increased appetite (30%).
A high proportion of respondents reported improvement in sleep (53%), alertness (71%), and mood (63%) during CBD therapy… this study suggests a potential role for CBD in the treatment of refractory childhood epilepsy including IS and LGS…”
http://www.ncbi.nlm.nih.gov/pubmed/25935511